SG11202003014VA - Cap-dependent endonuclease inhibitors - Google Patents
Cap-dependent endonuclease inhibitorsInfo
- Publication number
- SG11202003014VA SG11202003014VA SG11202003014VA SG11202003014VA SG11202003014VA SG 11202003014V A SG11202003014V A SG 11202003014VA SG 11202003014V A SG11202003014V A SG 11202003014VA SG 11202003014V A SG11202003014V A SG 11202003014VA SG 11202003014V A SG11202003014V A SG 11202003014VA
- Authority
- SG
- Singapore
- Prior art keywords
- cap
- dependent endonuclease
- endonuclease inhibitors
- inhibitors
- dependent
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Virology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pulmonology (AREA)
- Molecular Biology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862620065P | 2018-01-22 | 2018-01-22 | |
| PCT/US2019/014461 WO2019144089A1 (en) | 2018-01-22 | 2019-01-22 | Cap-dependent endonuclease inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11202003014VA true SG11202003014VA (en) | 2020-04-29 |
Family
ID=67299629
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11202003014VA SG11202003014VA (en) | 2018-01-22 | 2019-01-22 | Cap-dependent endonuclease inhibitors |
Country Status (22)
| Country | Link |
|---|---|
| US (1) | US10596171B2 (zh) |
| EP (1) | EP3743424A4 (zh) |
| JP (1) | JP6994121B2 (zh) |
| KR (1) | KR102432975B1 (zh) |
| CN (1) | CN110300753B (zh) |
| AU (1) | AU2019209426B2 (zh) |
| BR (1) | BR112020014810A2 (zh) |
| CA (1) | CA3078391C (zh) |
| CL (1) | CL2020001919A1 (zh) |
| CO (1) | CO2020006411A2 (zh) |
| EA (1) | EA202090658A1 (zh) |
| IL (1) | IL274199B (zh) |
| JO (1) | JOP20200159A1 (zh) |
| MX (1) | MX2020007722A (zh) |
| MY (1) | MY197875A (zh) |
| NZ (1) | NZ763248A (zh) |
| PE (1) | PE20211240A1 (zh) |
| PH (1) | PH12020550921A1 (zh) |
| SG (1) | SG11202003014VA (zh) |
| TW (1) | TWI714951B (zh) |
| WO (1) | WO2019144089A1 (zh) |
| ZA (1) | ZA202002037B (zh) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2020015669A1 (zh) * | 2018-07-17 | 2020-01-23 | 南京明德新药研发有限公司 | 抗流感病毒三并环衍生物 |
| CN112521386B (zh) * | 2019-09-19 | 2023-05-26 | 周雨恬 | 具有抗病毒作用的多环吡啶酮化合物及其药物组合和用途 |
| CN112574170A (zh) * | 2019-09-29 | 2021-03-30 | 江西东邦药业有限公司 | 一种二苯并七元环衍生物及其制备方法和应用 |
| CN112920202A (zh) * | 2019-12-05 | 2021-06-08 | 北京凯因科技股份有限公司 | 一种帽依赖性蛋白酶抑制剂 |
| CN113620948B (zh) * | 2020-05-06 | 2022-11-25 | 太景医药研发(北京)有限公司 | 帽依赖性核酸内切酶抑制剂 |
| US11639349B2 (en) * | 2020-05-28 | 2023-05-02 | Taigen Biotechnology Co., Ltd. | Stereoselective synthesis of intermediate for preparation of heterocyclic compound |
| CN113603689B (zh) * | 2020-09-08 | 2023-07-21 | 石家庄迪斯凯威医药科技有限公司 | 多环吡啶酮化合物及其药物组合物和用途 |
| CN113683613B (zh) * | 2020-09-08 | 2023-06-09 | 知和(山东)大药厂有限公司 | 一种多环吡啶肟基化合物及其药物组合物和用途 |
| CA3203543A1 (en) | 2020-12-30 | 2022-07-07 | Rhythm Mehra | Additively manufactured cable gland |
| AU2022205484A1 (en) * | 2021-01-08 | 2023-08-24 | Medshine Discovery Inc. | Pyridone multiple-membered ring derivatives and use thereof |
| WO2023072292A1 (zh) * | 2021-11-01 | 2023-05-04 | 南京知和医药科技有限公司 | 一种高效抗病毒化合物及其用途 |
| WO2024002054A1 (en) * | 2022-06-27 | 2024-01-04 | Taigen Biotechnology Co., Ltd. | Pharmaceutical composition comprising a cap-dependent endonuclease inhibitor |
| CN116284048B (zh) * | 2023-05-18 | 2023-08-15 | 长沙晶易医药科技股份有限公司 | 一种化合物及其制备方法、药物组合物和用途 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HUE038837T2 (hu) * | 2009-06-15 | 2018-11-28 | Shionogi & Co | Helyettesített policiklusos karbamoilpiridon-származék |
| PL2620436T3 (pl) | 2010-09-24 | 2018-10-31 | Shionogi & Co., Ltd. | Prolek podstawionej policyklicznej pochodnej karbamoilopirydonowej |
| MD3428170T2 (ro) * | 2015-04-28 | 2021-06-30 | Shionogi & Co | Derivat de piridonă policiclică anti-gripal și promedicament al acestuia |
| TW201726678A (zh) | 2015-10-30 | 2017-08-01 | 赫孚孟拉羅股份公司 | 嘧啶酮衍生物及其於治療、改善或預防病毒性疾病之用途 |
| WO2017109088A1 (en) | 2015-12-23 | 2017-06-29 | Savira Pharmaceuticals Gmbh | Pyrimidone derivatives and their use in the treatment, amelioration or prevention of a viral disease |
| JP6806413B2 (ja) * | 2016-02-03 | 2021-01-06 | 塩野義製薬株式会社 | 多環性ピリドン誘導体およびそのプロドラッグ |
-
2019
- 2019-01-18 US US16/251,652 patent/US10596171B2/en active Active
- 2019-01-19 TW TW108102141A patent/TWI714951B/zh active
- 2019-01-22 AU AU2019209426A patent/AU2019209426B2/en active Active
- 2019-01-22 SG SG11202003014VA patent/SG11202003014VA/en unknown
- 2019-01-22 EA EA202090658A patent/EA202090658A1/ru unknown
- 2019-01-22 MY MYPI2020002037A patent/MY197875A/en unknown
- 2019-01-22 KR KR1020207019652A patent/KR102432975B1/ko active IP Right Grant
- 2019-01-22 JO JOP/2020/0159A patent/JOP20200159A1/ar unknown
- 2019-01-22 BR BR112020014810-5A patent/BR112020014810A2/pt active Search and Examination
- 2019-01-22 CA CA3078391A patent/CA3078391C/en active Active
- 2019-01-22 JP JP2020561569A patent/JP6994121B2/ja active Active
- 2019-01-22 NZ NZ763248A patent/NZ763248A/en unknown
- 2019-01-22 EP EP19741704.1A patent/EP3743424A4/en active Pending
- 2019-01-22 MX MX2020007722A patent/MX2020007722A/es unknown
- 2019-01-22 PE PE2020000545A patent/PE20211240A1/es unknown
- 2019-01-22 WO PCT/US2019/014461 patent/WO2019144089A1/en unknown
- 2019-01-22 CN CN201980001275.8A patent/CN110300753B/zh active Active
-
2020
- 2020-04-23 IL IL274199A patent/IL274199B/en unknown
- 2020-05-04 ZA ZA2020/02037A patent/ZA202002037B/en unknown
- 2020-05-27 CO CONC2020/0006411A patent/CO2020006411A2/es unknown
- 2020-06-16 PH PH12020550921A patent/PH12020550921A1/en unknown
- 2020-07-22 CL CL2020001919A patent/CL2020001919A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| JP6994121B2 (ja) | 2022-01-14 |
| CA3078391A1 (en) | 2019-07-25 |
| NZ763248A (en) | 2023-06-30 |
| TWI714951B (zh) | 2021-01-01 |
| AU2019209426B2 (en) | 2020-11-19 |
| CN110300753B (zh) | 2022-01-04 |
| KR102432975B1 (ko) | 2022-08-16 |
| CA3078391C (en) | 2022-08-16 |
| PH12020550921A1 (en) | 2021-05-31 |
| BR112020014810A2 (pt) | 2020-12-08 |
| ZA202002037B (en) | 2021-08-25 |
| US20190224198A1 (en) | 2019-07-25 |
| CN110300753A (zh) | 2019-10-01 |
| PE20211240A1 (es) | 2021-07-09 |
| EA202090658A1 (ru) | 2020-10-12 |
| JOP20200159A1 (ar) | 2022-10-30 |
| EP3743424A4 (en) | 2021-10-06 |
| TW201938166A (zh) | 2019-10-01 |
| US10596171B2 (en) | 2020-03-24 |
| WO2019144089A1 (en) | 2019-07-25 |
| EP3743424A1 (en) | 2020-12-02 |
| IL274199A (en) | 2020-06-30 |
| KR20200086385A (ko) | 2020-07-16 |
| IL274199B (en) | 2021-07-29 |
| CO2020006411A2 (es) | 2020-06-09 |
| JP2021512146A (ja) | 2021-05-13 |
| MY197875A (en) | 2023-07-21 |
| CL2020001919A1 (es) | 2020-10-09 |
| MX2020007722A (es) | 2020-09-09 |
| AU2019209426A1 (en) | 2020-04-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA202002037B (en) | Cap-dependent endonuclease inhibitors | |
| IL283639A (en) | kif18a inhibitors | |
| IL276594A (en) | FAP inhibitors | |
| SG11202009933WA (en) | Bcl-2 INHIBITORS | |
| ZA202104029B (en) | Rad51 inhibitors | |
| GB201800298D0 (en) | Method | |
| ZA202006327B (en) | Magl inhibitors | |
| IL280486A (en) | Carboxamides as ubiquitin-specific protease inhibitors | |
| ZA202106284B (en) | Rad51 inhibitors | |
| ZA201907136B (en) | Ip6k inhibitors | |
| IL276013A (en) | pi4kiiibeta inhibitors | |
| IL281514A (en) | O-glycoprotein-2-acetamido-2-deoxy-3-D-glucopyranosidase inhibitors | |
| IL279419A (en) | CCL5 inhibitors | |
| IL274550A (en) | Dopamine-B-hydroxylase inhibitors | |
| GB201819839D0 (en) | MAP4K4 inhibitors | |
| GB2578396B (en) | Amidodiamine corrosion inhibitors | |
| GB201800187D0 (en) | Method | |
| GB201812462D0 (en) | Inhibitors | |
| GB201810765D0 (en) | SRPK1 inhibitors | |
| GB201908044D0 (en) | Dopamine-B-Hydroxylase inhibitors | |
| GB201905476D0 (en) | MAPA4K4 Inhibitors | |
| GB201809939D0 (en) | Eastase inhibitor | |
| GB201813252D0 (en) | MAP4K4 inhibitors | |
| GB201721465D0 (en) | Inhibitors | |
| GB201720189D0 (en) | Dopamine-B-hydroxylase inhibitors |